drugset
drugset / Trial / NCT04709081

A Drug Interaction Study of ACH-0145228

NCT04709081 ↗

Phase 1 Completed 38 enrolled Alexion Pharmaceuticals, Inc. Achillion, a wholly owned subsidiary of Alexion · collabCelerion · collab
RandomizedParallel-groupOpen-labelBasic science

Summary

This was a 2-part study (Part 1 and Part 2), with each part being an open-label, fixed sequence, 2-period study in healthy adult participants.

Timeline

Start
2019-12-22
Primary completion
2020-04-16
Completion
2020-04-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.25 mg —
Subject Itraconazole Small molecule 200 mg Oral
Subject Midazolam Small molecule 2 mg —
Subject Vemircopan Small molecule 40 mg —
Subject Vemircopan Small molecule 120 mg —

Indications

No indication recorded.